4th Quarter - Report

WILLIAMS AND JENSEN, PLLC for PHRMA

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

IP Protections related to trade agreements; trade policies impacting pharmaceutical development.

LobbyistCovered position, as disclosed
SUSAN HIRSCHMANN COS, Rep.Van Hilleary and Majority Whip
MATTHEW B HOEKSTRA —
CHERYL LYNN JAEGER Shared employee, Ofc of the Speaker & Ofc of VA 07; Sr Policy Adv, Maj Leader, Rep. Cantor; Sr Policy Adv, Republican Whip, Rep. Cantor; Sr Policy Adv, Majority Whip, Rep. Blunt; Prof Staff House Committee on E & C; Sr LA to Rep. Cox

Contacted: Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Drug Pricing Program. CMMI Medicare Part B Demonstration. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 1865, Further Consolidated Appropriations Act 2020.

LobbyistCovered position, as disclosed
SUSAN HIRSCHMANN —
MATTHEW B HOEKSTRA —
CHERYL LYNN JAEGER —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE

Bills named: H.R. 1865 (116th), S. 2543 (116th), H.R. 3 (116th)

Medicare/Medicaid MMM

General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Drug Pricing Program. IPI drug pricing proposal, Medicare Rebate Rule. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 1865, Further Consolidated Appropriations Act 2020.

LobbyistCovered position, as disclosed
SUSAN HIRSCHMANN —
MATTHEW B HOEKSTRA —
CHERYL LYNN JAEGER —
KARINA LYNCH —
GEORGE OLSEN —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 2543 (116th), H.R. 1865 (116th), H.R. 3 (116th)

Budget/Appropriations BUD

Issues related to pharmaceutical development; Policies impacting Medicare Part D.

LobbyistCovered position, as disclosed
SUSAN HIRSCHMANN COS, Rep Van Hilleary and Majority Whip
MATTHEW B HOEKSTRA —
CHERYL LYNN JAEGER Shrd employee, Ofc of the Speaker & Ofc of VA 7; Sr Policy Adv, Maj Leader, Rep Cantor; Sr. Policy Adv, Republican Whip, Rep Cantor; Sr. Policy Adv, Maj Whip, Rep Roy Blunt; Prof Staff House Committee E&C; SR LA Rep Cox.

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.